| First Author | Langer V | Year | 2019 |
| Journal | J Clin Invest | Volume | 129 |
| Issue | 11 | Pages | 4691-4707 |
| PubMed ID | 31566580 | Mgi Jnum | J:280958 |
| Mgi Id | MGI:6370345 | Doi | 10.1172/JCI124884 |
| Citation | Langer V, et al. (2019) IFN-gamma drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. J Clin Invest 129(11):4691-4707 |
| abstractText | Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with rising incidence. Diseased tissues are heavily vascularized. Surprisingly, the pathogenic impact of the vasculature in IBD and the underlying regulatory mechanisms remain largely unknown. IFN-gamma is a major cytokine in IBD pathogenesis, but in the context of the disease, it is almost exclusively its immune-modulatory and epithelial cell-directed functions that have been considered. Recent studies by our group demonstrated that IFN-gamma also exerts potent effects on blood vessels. Based on these considerations, we analyzed the vessel-directed pathogenic functions of IFN-gamma and found that it drives IBD pathogenesis through vascular barrier disruption. Specifically, we show that inhibition of the IFN-gamma response in vessels by endothelial-specific knockout of IFN-gamma receptor 2 ameliorates experimentally induced colitis in mice. IFN-gamma acts pathogenic by causing a breakdown of the vascular barrier through disruption of the adherens junction protein VE-cadherin. Notably, intestinal vascular barrier dysfunction was also confirmed in human IBD patients, supporting the clinical relevance of our findings. Treatment with imatinib restored VE-cadherin/adherens junctions, inhibited vascular permeability, and significantly reduced colonic inflammation in experimental colitis. Our findings inaugurate the pathogenic impact of IFN-gamma-mediated intestinal vessel activation in IBD and open new avenues for vascular-directed treatment of this disease. |
